Loading..

Radius Health, Inc. (RDUS) Report Analysis

Corporate Events

Neutral

Radius Health, Inc Provides Information to the ...

2022-06-27 16:19:00

On June 27, 2022, the Board of Directors of Radius Health, Inc announced that they determined to postpone the 2022 annual meeting, which will ...

Positive

Velan Capital Investment Comments on Proposed S...

2022-06-24 16:19:00

On June 24, 2022, Velan Capital Investment Management LP and Repertoire Partners LP issued a press release commenting in response to the propo...

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Rus...

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell 3000E Index

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Rus...

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell 3000E Growth Index

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Rus...

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell Microcap Growth Index

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Rus...

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell Microcap Index

Positive

Gurnet Point Capital Limited, Patient Square Ca...

2022-06-23 13:46:00

Gurnet Point Capital Limited, Patient Square Capital, LP, Radius Health, Inc. - M&A Call

Positive

Patient Square Capital, LP and Gurnet Point Cap...

2022-06-23 00:00:00

Patient Square Capital, LP and Gurnet Point Capital Limited entered into a definitive agreement to acquire Radius Health, Inc. (NasdaqGM:RDUS)...

Positive

Menarini Group and Radius Health Submit New Dru...

2022-06-22 22:24:00

The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") announced that Menarini, with support from Radius, has submitted a New Drug...

Positive

Velan Capital Releases Presentation to Sharehol...

2022-06-21 16:30:00

On June 21, 2022, Velan Capital Investment Management LP and Repertoire Partners LP announced that it has issued a detailed presentation on th...

Neutral

Velan Capital Investment Management LP Solicits...

2022-06-21 10:02:00

On June 21, 2022, Velan Capital Investment Management LP has filed a definitive proxy statement and urged the shareholders of Radius Health In...

Positive

Rubric Capital Supports Velan Capital Investment

2022-06-16 14:00:00

On June 16, 2022, Rubric Capital Management LP sent a letter to Radius Health, Inc.’s Board of Directors. In its letter, Rubric Capital outlin...

Positive

Velan Capital Investment Responds to Radius Hea...

2022-06-13 17:25:00

On June 13, 2022, Velan Capital Investment Management LP and Repertoire Partners LP responded to recent statements made by Radius Health, Inc....

Positive

Radius Health Expands Non-Us Market Footprint f...

2022-06-08 12:00:00

Radius Health, Inc. provided an update on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection. Radius has entered i...

Neutral

Velan Capital-Repertoire Group Files Definitive...

2022-06-07 17:10:00

On June 7, 2022, Velan Capital Investment Management LP and Repertoire Partners LP announced that it has filed definitive proxy materials in c...

Neutral

Velan Capital Solicits Proxies from Shareholder...

2022-06-06 17:12:00

On June 6, 2022, Velan Capital Partners LP filed a definitive proxy statement soliciting proxies and urged the shareholders of Radius Health, ...

Positive

Menarini Group and Radius Health, Inc. Present ...

2022-06-06 13:00:00

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) announced the presentation at the 2022 American Society of Clinical Oncolog...

Neutral

Radius Health, Inc. Presents at The 2022 ASCO A...

2022-06-06 13:00:00

Radius Health, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Radius Health Inc Sends Letter to Shareholders

2022-06-06 07:01:00

On June 6, 2022, Radius Health Inc announced that it has sent a letter to shareholders and stated that it has filed a definitive proxy stateme...

Positive

Radius Health, Inc. Provides Update on Abalopar...

2022-06-01 20:15:00

Radius Health, Inc. provided an update on the abaloparatide transdermal system (abalo-TDS) development program. Company ascertained regulatory...

Positive

Velan LP Provides Information to Shareholders o...

2022-05-25 09:06:00

On May 25, 2022, Velan LP announced that it has withdrew its nomination of R. John Fletcher for election as a director. In addition, Velan LP ...

Negative

Radius Health, Inc. Appoints Jennifer A. Jarret...

2022-05-20 13:00:00

Radius Health, Inc. announced that it has added two new independent members to the Board of Directors (the “Board”). Effective immediately, Je...

Neutral

Radius Health Inc Solicits Proxies from Shareholders

2022-05-20 00:00:00

On May 20, 2022, Radius Health Inc announced that it has filed a preliminary proxy statement and urged the shareholders to vote for its board ...

Neutral

Radius Health, Inc. Provides Earnings Guidance ...

2022-05-05 11:30:00

Radius Health, Inc. provided earnings guidance for the full year 2022. For the year, the company expects $232 million TYMLOS Net Revenue (42% ...

Neutral

Radius Health, Inc. to Report Q1, 2022 Results ...

2022-04-25 12:30:00

Radius Health, Inc. announced that they will report Q1, 2022 results on May 05, 2022

Neutral

Radius Health, Inc., Q1 2022 Earnings Call, May...

2022-04-25 12:30:00

Radius Health, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Velan Capital Solicits Proxies from Shareholder...

2022-04-18 16:09:00

On April 18, 2022, Velan Capital Partners LP filed a preliminary proxy statement and urged the shareholders of Radius Health, Inc. to vote for...

Neutral

Radius Health, Inc. Presents at Bank of America...

2022-03-22 05:03:00

Radius Health, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 05:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S,...

Neutral

Radius Health, Inc. - Special Call

2022-03-03 21:05:00

To focus in RADO11

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Positive

Radius Announces Update on TYMLOS® (abaloparati...

2021-12-23 13:30:00

Radius Health, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

Radius Health, Inc. - Special Call

2021-12-08 14:00:00

To discuss topline results from the wearABLe Phase 3 trial; and to review data presented at the San Antonio Breast Cancer Symposium from the E...

Positive

Radius Health, Inc. Announces Results from the ...

2021-12-08 14:00:00

Radius Health, Inc. announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal...

Negative

Radius Health, Inc. Announces Executive Changes

2021-11-15 22:01:00

Radius Health, Inc. announced that effective November 12, 2021, Salvador Grausso III transitioned from his role as Chief Commercial Officer of...

Neutral

Radius Health, Inc. Presents at Stifel 2021 Vir...

2021-11-11 13:30:00

Radius Health, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 08:40 AM. Venue: New York, New York, United States.

Neutral

Radius Health, Inc. to Report Q3, 2021 Results ...

2021-10-20 19:00:00

Radius Health, Inc. announced that they will report Q3, 2021 results on Nov 08, 2021

Neutral

Radius Health, Inc., Q3 2021 Earnings Call, Nov...

2021-10-20 19:00:00

Radius Health, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Positive

Menarini Group and Radius Health Announce Posit...

2021-10-20 12:30:00

the Menarini Group and Radius Health, Inc. announced positive topline results from the EMERALD study. The study was designed to evaluate elace...

Positive

Radius Announces Positive Phase 3 Topline Resul...

2021-10-18 12:30:00

Radius Health, Inc. announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males w...

Neutral

Radius Health, Inc. Amends Article X of the Ame...

2021-09-27 21:01:00

Effective September 22, 2021, the Board of Directors of Radius Health, Inc. amended Article X of the Company’s Amended and Restated Bylaws to ...

Negative

Radius Health, Inc. Announces Executive Changes

2021-08-26 10:24:00

On August 23, 2021, James G. Chopas tendered his resignation as the Principal Financial Officer, Principal Accounting Officer and Treasurer of...

Positive

Radius Health Announces Plans for Global Prader...

2021-07-22 13:00:00

Radius Health, Inc. announced that it has received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Adm...

Neutral

Radius Health, Inc., Q2 2021 Earnings Call, Aug...

2021-07-20 21:10:00

Radius Health, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Radius Health, Inc. to Report Q2, 2021 Results ...

2021-07-20 21:10:00

Radius Health, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Neutral

Radius Health, Inc Provides Information to the Shareholders

2022-06-27 16:19:00

On June 27, 2022, the Board of Directors of Radius Health, Inc announced that they determined to postpone the 2022 annual meeting, which will now be held virtually on July 26, 2022. The Company stated that the postponement will provide the Company’s stockholders additional time to evaluate information regarding the proposed tender offer for all the outstanding shares of the Company’s common stock, $0.0001 par value to be launched by an entity jointly owned by Gurnet Point Capital, LLC and Patient Square Capital pursuant to an Agreement and Plan of Merger between the Company, Ginger Acquisition, Inc. (Parent) and Ginger Merger Sub, Inc. (Purchaser), disclosed by the Company on June 23, 2022, as well as the Board’s strategic review process. In addition, the Company stated that pursuant to the merger agreement, Purchaser has agreed to commence the offer by July 15, 2022.

Positive

Velan Capital Investment Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital

2022-06-24 16:19:00

On June 24, 2022, Velan Capital Investment Management LP and Repertoire Partners LP issued a press release commenting in response to the proposed acquisition of Radius Health, Inc. by Gurnet Point Capital and Patient Square Capital in a transaction valued at up to approximately $890 million.

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell 3000E Index

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell 3000E Index

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell 3000E Growth Index

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell 3000E Growth Index

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell Microcap Growth Index

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell Microcap Growth Index

Positive

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell Microcap Index

2022-06-24 00:00:00

Radius Health, Inc.(NasdaqGM:RDUS) added to Russell Microcap Index

Positive

Gurnet Point Capital Limited, Patient Square Capital, LP, Radius Health, Inc. - M&A Call

2022-06-23 13:46:00

Gurnet Point Capital Limited, Patient Square Capital, LP, Radius Health, Inc. - M&A Call

Positive

Patient Square Capital, LP and Gurnet Point Capital Limited entered into a definitive agreement to acquire Radius Health, Inc. (NasdaqGM:RDUS) for approximately $500 million.

2022-06-23 00:00:00

Patient Square Capital, LP and Gurnet Point Capital Limited entered into a definitive agreement to acquire Radius Health, Inc. (NasdaqGM:RDUS) for approximately $500 million on June 23, 2022. Under the terms of the merger agreement, an entity jointly owned by Gurnet Point and Patient Square will initiate a tender offer to acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a CVR (Contingent Value Right) of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $300 million (inclusive of U.S. sales and Japan royalties or supply payments based on supply of TYMLOS for sale in Japan) during any consecutive 12-month period prior to December 31, 2025. Each CVR represents the right to receive a contingent payment of $1.00 in cash. Debt financing for this transaction will be provided by OrbiMed Advisors, LLC. Concurrently with the execution of the Merger Agreement, buyers entered into a debt commitment letter dated June 23, 2022, pursuant to which, and subject to the terms and conditions set forth therein, the commitment party thereto committed to provide, at the Effective Time, debt financing in an aggregate principal amount of $350 million to finance the transactions contemplated by the Merger Agreement and to pay related fees and expenses. Upon completion, Radius will become a private company and will no longer be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, nor be traded on Nasdaq Global Market. The Company plans to maintain operations in the Boston, MA and Wayne, PA areas. Upon termination of the Merger Agreement by Radius, under certain circumstances, Radius will be required to pay Parent a termination fee in an amount equal to $16.15 million. Additionally, upon termination of the Merger Agreement by Patient Square Capital, LP and Gurnet Point Capital Limited, Patient Square Capital, LP and Gurnet Point Capital Limited will be required to pay a termination fee in an amount equal to $22.64 million. Consummation of the Offer is subject to certain conditions, including: (i) immediately prior to the expiration of the Offer (as extended in accordance with the Merger Agreement) the number of Shares validly tendered, and not validly withdrawn, is at least one more than 50% of the total number of Shares outstanding at the time of the expiration of the Offer (the “Minimum Condition”); (ii) immediately prior to the expiration of the Offer (as extended in accordance with the Merger Agreement), any waiting period (and any extensions thereof) and any approvals or clearances applicable to the consummation of the transactions contemplated by the Merger Agreement in accordance with the Hart-Scott-Rodino Antitrust Improvements Act of 1976 have expired or been terminated or obtained, as applicable, receipt of regulatory approvals and other conditions. The transaction is not subject to a financing condition. Transaction has been unanimously approved by the Radius Board. Radius’ Board of directors unanimously recommends that Radius shareholders tender their shares in the tender offer. Upon the successful completion of the tender offer, any remaining shares of common stock of Radius that were not tendered in the tender offer will be canceled and converted into the right to receive the same consideration payable in the tender offer. The board of directors of Patient Square Capital, LP and Gurnet Point Capital Limited also approved the Offer. As of June 27, 2022, the annual meeting of Radius is scheduled on July 26, 2022. Transaction is expected to close in the third quarter of 2022. J.P. Morgan Securities LLC acted as exclusive financial advisor to Radius and Zachary R. Blume and Marc A. Rubenstein of Ropes & Gray LLP serving as its legal advisors. Goldman Sachs & Co. LLC acted as exclusive financial advisor to Gurnet Point Capital and Patient Square Capital. Peter Handrinos and Leah Sauter of Latham & Watkins, LLP serving as Gurnet Point Capital’s legal advisors. Michael Weisser, Daniel E. Wolf, Jason Kanner, Mark Schwed, Shaun J. Mathew and Maggie Flores of Kirkland & Ellis LLP serving as Patient Square Capital’s legal advisors. Covington & Burling LLP is serving as OrbiMed’s legal advisor. J.P. Morgan Securities LLC acted as fairness opinion provider to Radius board.

Positive

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

2022-06-22 22:24:00

The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer. As part of the submission, the Companies have requested Priority Review with the FDA. If Priority Review is granted, the Companies anticipate that the FDA would conduct an 8-month review, incorporating a 6-month priority designation review. The NDA submission is based on positive phase 3 data from the EMERALD study that was previously announced on October 20, 2021. EMERALD met both of its primary endpoints, which were progression-free survival (PFS) in the overall population and PFS in the estrogen receptor 1 (ESR1) mutation subgroup as compared to standard of care (SoC) with the options of fulvestrant or an aromatase inhibitor. Elacestrant is the first and currently only investigational oral SERD to show positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men. Notably, these results showed elacestrant is also active in patients whose tumors harbor an ESR1 mutation, one of the key resistance mechanisms that develops in later treatment lines of metastatic breast cancer. Following the completion of EMERALD, data from the study was presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8, 2021, published in the Journal of Clinical Oncology (JCO) on May 18, 2022, and further subset analyses were presented at the 2022 American Society of Clinical Oncology (ASCO) annual Meeting on June 6, 2022. With the submission of the NDA, based on the original agreement of the Companies, Menarini takes over activities and will be responsible for registration and commercialization. Menarini plans to use its fully owned subsidiary in the U.S., Stemline Therapeutics, to commercialize elacestrant if approved by the FDA. Elacestrant is an investigational selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/HER2- advanced breast cancer. In 2018, elacestrant received fast track designation from the FDA. Preclinical studies completed prior to EMERALD indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. The study enrolled 477 patients who have received prior treatment with one or two lines of endocrine therapy, including a CDK 4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator's choice of an approved hormonal agent. The primary endpoint of the study was progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints included evaluation of overall survival (OS), objective response rate (ORR), and duration of response (DOR).

Positive

Velan Capital Releases Presentation to Shareholders of Radius Health

2022-06-21 16:30:00

On June 21, 2022, Velan Capital Investment Management LP and Repertoire Partners LP announced that it has issued a detailed presentation on the need for board-level change at Radius Health, Inc. in connection with the upcoming 2022 annual meeting of stockholders to be held on July 8, 2022. Velan Capital- Repertoire Partners also mailed a letter to fellow stockholders detailing the Board of Directors’ track record of value destruction and calling on the Company stockholders to send a message to the Board at the upcoming annual meeting that the status quo can no longer continue. Velan Capital- Repertoire Partners stated that it urges all stockholders to vote for change on Velan Capital’s proxy card to elect Eric Ende, Cynthia Flowers, and Ann MacDougall.

Neutral

Velan Capital Investment Management LP Solicits Proxies from Shareholders of Radius Health Inc

2022-06-21 10:02:00

On June 21, 2022, Velan Capital Investment Management LP has filed a definitive proxy statement and urged the shareholders of Radius Health Inc to vote for its board nominees at the 2022 annual meeting of shareholders.

Positive

Rubric Capital Supports Velan Capital Investment

2022-06-16 14:00:00

On June 16, 2022, Rubric Capital Management LP sent a letter to Radius Health, Inc.’s Board of Directors. In its letter, Rubric Capital outlines value enhancing initiatives to address the Company’s underperformance and poor corporate governance: (1) maximize the value of Tymlos, (2) maximize the value of the elacestrant royalty, (3) generate cash flows to maximize the value of the Company’s tax attributes, and (4) put in place and empower the best possible team. Rubric Capital stated that due to a lack of confidence in the Company’s current Board and management team to execute on these initiatives, Rubric Capital intends to vote for the 3 director candidates nominated by Velan Capital Investment Management and Repertoire Partners – Eric Ende, Cynthia Flowers, and Ann MacDougall – at the Company’ upcoming annual meeting of stockholders to be held on July 8, 2022.

Positive

Velan Capital Investment Responds to Radius Health’s Board

2022-06-13 17:25:00

On June 13, 2022, Velan Capital Investment Management LP and Repertoire Partners LP responded to recent statements made by Radius Health, Inc.’s Board of Directors. Velan Capital Investment stated that the Company touts its internal activism, but the facts reveal a conflicted Board that has failed to provide proper oversight of CEO G. Kelly Martin or instill a culture of accountability. Velan Capital Investment also stated that the Company has experienced a 49% decline in stock price, 60% employee turnover and 10% reduction in TYMLOS revenue in the first 24 months of CEO G. Kelly Martin’s tenure. Velan Capital Investment added that it urges all stockholders to vote for change on Velan Capital Investment’s proxy card to elect Eric Ende, Cynthia Flowers, and Ann MacDougall at the Company’s annual shareholders meeting.

Positive

Radius Health Expands Non-Us Market Footprint for Tymlos

2022-06-08 12:00:00

Radius Health, Inc. provided an update on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection. Radius has entered into agreements with the following companies and markets for TYMLOS: Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco. Pharmbio Korea Inc.: South Korea, Biosidus: Colombia, South America. These agreements add 13 new countries to the current non-US countries of Japan, partnered with Teijin Pharma Limited, and Canada, partnered with Paladin Labs Inc. In accordance with the terms of the agreements, each company will register, commercialize, and distribute TYMLOS on an exclusive basis in their respective territories. These counterparties will be responsible for all commercial activities related to TYMLOS including sales, marketing, medical affairs, pricing, and reimbursement. Radius will be responsible for supplying the drug to each company. Radius will receive upfront payments, regulatory and commercial milestones, and a portion of the total consideration as part of the Cost of Goods Sold.

Neutral

Velan Capital-Repertoire Group Files Definitive Proxy Materials in Connection with Radius Health

2022-06-07 17:10:00

On June 7, 2022, Velan Capital Investment Management LP and Repertoire Partners LP announced that it has filed definitive proxy materials in connection with its nomination of Eric Ende, Cynthia Flowers, and Ann MacDougall to Radius Health, Inc.’s Board of Directors at the Company’s 2022 annual meeting of stockholders. Velan Capital-Repertoire Partners also announced that it has mailed a letter to fellow stockholders detailing the Board’s troubling track record of value destruction and calling on the Company stockholders to send a message to the Board at the upcoming annual meeting to be held on July 8, 2022, that meaningful change is immediately required. Velan Capital-Repertoire also launched a website, fixradius.com, which contains important stockholder materials in connection with its campaign, including its definitive proxy statement for the annual meeting and instructions for contacting its proxy solicitor, Okapi Partners.

Neutral

Velan Capital Solicits Proxies from Shareholders of Radius Health

2022-06-06 17:12:00

On June 6, 2022, Velan Capital Partners LP filed a definitive proxy statement soliciting proxies and urged the shareholders of Radius Health, Inc. to vote for the election of its 3 nominees, Eric J. Ende, Cynthia L. Flowers, and Ann MacDougall, as directors to serve until the 2025 annual meeting of stockholders and until their respective successors are duly elected and qualified.

Positive

Menarini Group and Radius Health, Inc. Present A Subgroup Analysis from the Elacestrant Pivotal Phase 3 EMERALD Clinical Trial At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

2022-06-06 13:00:00

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) announced the presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting of data from the EMERALD phase 3 clinical trial (NCT03778931). In a non-pre-specified subgroup analysis of patients with ER+/HER2- metastatic breast cancer (mBC) without prior chemotherapy in the metastatic setting, elacestrant significantly prolonged progression-free survival (PFS) compared to standard of care (SOC) endocrine therapy. EMERALD study met both of its pre-specified primary endpoints of progression free survival (PFS) in the overall population and in patients with ESR1 mutation (mESR1). 77.8% (n=371) out of the 477 patients enrolled in the trial had not received prior chemotherapy in the metastatic setting for ER+/HER2- mBC. Among these patients, elacestrant showed the following results compared to SOC: 31% reduction in the risk of progression or death in all patients (HR=0.681 [95% CI: 0.520 – 0.891]; P=0.00388) and prolonged median PFS (3.68 vs 1.97 months). 46% reduction in the risk of progression or death in patients with mESR1 (HR=0.535 [95% CI: 0.356 – 0.799]; P=0.00235) and prolonged median PFS (5.32 vs 1.91 months). At 6 months, PFS rate with elacestrant was 38.18% vs. 23.47% with SOC in the overall population, and 43.79% vs. 23.83% in the ESR1 mutation population. PFS rate at 12 months with elacestrant was 27.12% vs. 12.19% with SOC in the overall population, and 31.48% vs. 12.36% in the ESR1 mutation population. In exploratory subgroup analyses, elacestrant significantly reduced the risk of progression or death and prolonged median PFS vs fulvestrant in all patients without prior chemotherapy (HR=0.636 [95% CI: 0.465-0.868]; median PFS 3.68 vs 1.97 months; P=0.0032), and in patients with mESR1 without prior chemotherapy (HR=0.487 (95% CI: 0.310-0.761; median PFS 5.32 vs 1.91 months; P=0.0015). Elacestrant had a manageable safety profile in patients without prior chemotherapy consistent with the overall population. Elacestrant is an investigational selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/HER2- advanced breast cancer. In 2018, elacestrant received fast track designation from the FDA. Preclinical studies completed prior to EMERALD indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. The study enrolled 477 patients who have received prior treatment with one or two lines of endocrine therapy, including a CDK 4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator’s choice of an approved hormonal agent. The primary endpoint of the study was progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints included evaluation of overall survival (OS), objective response rate (ORR), and duration of response (DOR).

Neutral

Radius Health, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022

2022-06-06 13:00:00

Radius Health, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Radius Health Inc Sends Letter to Shareholders

2022-06-06 07:01:00

On June 6, 2022, Radius Health Inc announced that it has sent a letter to shareholders and stated that it has filed a definitive proxy statement with SEC in connection with requesting the shareholders to vote for its board nominees Catherine J. Friedman, Jean Pierre Garnier, and Andrew C. von Eschenbach and do not vote for Velan Capital Investment Management LP nominees at the annual meeting of shareholders scheduled to be held on July 8, 2022.

Positive

Radius Health, Inc. Provides Update on Abaloparatide Transdermal System

2022-06-01 20:15:00

Radius Health, Inc. provided an update on the abaloparatide transdermal system (abalo-TDS) development program. Company ascertained regulatory clarity for possible forward progression of abalo-TDS; Additional and successful clinical trial would be required to advance towards an NDA filing; New timeline for earliest possible abalo-TDS launch: 2H 2025; Based on regulatory clarity, timeline, and costs, Radius will cease all work on the program; Eliminates prospective program costs: $100+ million over 3+ years: CMC, clinical, and launch; Company continues to dynamically manage capital and its allocation, risk, and overall timelines. As previously reported on December 8, 2021, the Phase 3 results for abalo-TDS did not meet its primary endpoint of non-inferiority to abaloparatide subcutaneous injection (TYMLOS). The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to patients. Following the reported Phase 3 trial results, the Company outlined three requirements needed to move the abalo-TDS program forward. Those were regulatory clarity, a re-constructed supply chain and CMC agreement/economics and lastly, external funding. The company committed to providing clarity to the market by June of 2022. Regulatory feedback from the U.S. Food and Drug Administration (FDA) on abalo-TDS indicated an additional pivotal trial would be required to move forward with any regulatory filings. If successful, the company would then incorporate the newly generated data in a filing for future consideration by the FDA with the earliest possible launch timeline of 2H 2025. Given the clarity on the regulatory pathway, delayed commercial timelines, and $100+ million of additional capital required over the next 3+ years, Radius will cease all work on abalo-TDS.

Positive

Velan LP Provides Information to Shareholders of Radius Health Inc

2022-05-25 09:06:00

On May 25, 2022, Velan LP announced that it has withdrew its nomination of R. John Fletcher for election as a director. In addition, Velan LP stated that it intends to file a definitive proxy statement with the SEC and urged the shareholders of the Company to vote for its board nominees Eric J. Ende, Cynthia L. Flowers and Ann MacDougall at the 2022 annual meeting of shareholders.

Negative

Radius Health, Inc. Appoints Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

2022-05-20 13:00:00

Radius Health, Inc. announced that it has added two new independent members to the Board of Directors (the “Board”). Effective immediately, Jennifer A. Jarrett and Susan Vissers Lisa have joined the Board as Class I and Class III directors, respectively. In addition, Radius’ Board also announced several corporate governance changes to further enhance shareholder input. The appointments of Ms. Jarrett and Ms. Lisa further expand the Board’s gender diversity and relevant industry expertise, including senior-level experience at large public companies in the life sciences sector. Of the expanded Board’s 10 directors, nine are independent. Six of the Company’s current directors, including Ms. Jarrett and Ms. Lisa, have joined the Board in the past two years, reflecting adeliberate refreshment process across the Company’s leadership. Board Appointments: Jennifer A. Jarrett, 51, is currently Chief Operating Officer and serves on the Board of Arcus Biosciences, a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. She currently serves on the Board of Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing cancer therapies. She also serves on the Board of SMART, a non-profit organization whose mission is to help “first generation American” students access and assimilate into private schools in the Bay Area. She previously served as Vice President, Corporate Development and Capital Markets at Uber and on the boards of Arena Pharmaceuticals and Audentes Therapeutics. Earlier in her career she served in senior roles at Medivation, Citigroup Inc. and Credit Suisse Group AG. Ms. Jarrett earned a BA degree in Economics from Dartmouth College and an MBA from Stanford University Graduate School of Business. Susan Vissers Lisa, 53, recently served as Senior Vice President, Investor Relations of CVS Health Corporation through April 2022. Prior to this position, Ms. Lisa was Vice President, Investor Relations at Boston Scientific Corporation for over seven years. Previously, she served as Senior Director, Investor Relations and Corporate Development at Abiomed and held senior roles at BofA Securities, Inc. Ms. Lisa began her career at JPMorgan Chase and Cowen Inc. Ms. Lisa earned a BA degree in Economics and Political Science from Duke University and an MBA from New York University Stern School of Business. She is a CFA charter holder.

Neutral

Radius Health Inc Solicits Proxies from Shareholders

2022-05-20 00:00:00

On May 20, 2022, Radius Health Inc announced that it has filed a preliminary proxy statement and urged the shareholders to vote for its board nominees and other proposals at the annual meeting of shareholders scheduled to be held on July 8, 2022.

Neutral

Radius Health, Inc. Provides Earnings Guidance for the Full Year 2022

2022-05-05 11:30:00

Radius Health, Inc. provided earnings guidance for the full year 2022. For the year, the company expects $232 million TYMLOS Net Revenue (42% estimated in 1H and 58% in 2H 2022) and ($5) million to $5 million Net Loss.

Neutral

Radius Health, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-25 12:30:00

Radius Health, Inc. announced that they will report Q1, 2022 results on May 05, 2022

Neutral

Radius Health, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-25 12:30:00

Radius Health, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Velan Capital Solicits Proxies from Shareholders of Radius Health

2022-04-18 16:09:00

On April 18, 2022, Velan Capital Partners LP filed a preliminary proxy statement and urged the shareholders of Radius Health, Inc. to vote for its nominees by signing the proxy card.

Neutral

Radius Health, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 05:20 PM

2022-03-22 05:03:00

Radius Health, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 05:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Radius Health, Inc. - Special Call

2022-03-03 21:05:00

To focus in RADO11

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Positive

Radius Announces Update on TYMLOS® (abaloparatide) Label

2021-12-23 13:30:00

Radius Health, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal of the boxed warning regarding the risk of osteosarcoma. The removal of the boxed warning comes after a thorough regulatory review of long-term post-marketing data in TYMLOS and the parathyroid hormone (PTH) class of drugs. Additional labeling revisions include updates to the Warnings and Precautions section about the risk of osteosarcoma. TYMLOS (abaloparatide) injection: TYMLOS (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Radius Health, Inc. - Special Call

2021-12-08 14:00:00

To discuss topline results from the wearABLe Phase 3 trial; and to review data presented at the San Antonio Breast Cancer Symposium from the EMERALD Phase 3 trial

Positive

Radius Health, Inc. Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

2021-12-08 14:00:00

Radius Health, Inc. announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis. The wearABLe study did not meet its primary endpoint of NI for abalo-TDS 300 micrograms (ug) vs. TYMLOS 80 ug in the percent change from baseline in lumbar spine (LS) bone mineral density (BMD) at 12 months based on a NI margin of 2.0%. PRIMARY ENDPOINT; Abalo-TDS group demonstrated an increase of 7.1% (95% CI: 6.2, 8.0) vs. baseline. TYMLOS group demonstrated an increase of 10.9% (95% CI: 9.9, 11.8) vs. baseline. Treatment difference: -3.7% (95% CI: -5.0, -2.4). SECONDARY ENDPOINTS; % change in total hip and femoral neck BMD at 12 months vs. baseline: Abalo-TDS group: total hip and femoral neck BMD increased by an avg. of 2.0% and 1.9%. TYMLOS group: total hip and femoral neck BMD increased by an avg. of 3.7% and 3.4%. SAFETY RESULTS; Incidence of severe or serious treatment-emergent adverse events (TEAEs): similar in both groups. More subjects in the abalo-TDS group reported TEAEs related to the application site as compared to the TYMLOS group. Fewer subjects in the abalo-TDS group had TEAEs leading to study drug withdrawal, interruption, or discontinuation than in the TYMLOS group. DATA FROM PREVIOUS TYMLOS REGISTRATIONAL STUDY (ACTIVE, BA058-05-003). TYMLOS group LS BMD increase at 12 months vs. baseline: 9.1%. Teriparatide group LS BMD increase at 12 months vs. baseline: 7.9%. The wearABLe study data and technical details are to be analyzed and utilized as a basis for future abalo-TDS plans.

Negative

Radius Health, Inc. Announces Executive Changes

2021-11-15 22:01:00

Radius Health, Inc. announced that effective November 12, 2021, Salvador Grausso III transitioned from his role as Chief Commercial Officer of Radius Health, Inc. (the Company) to the Company’s Senior Vice President, Head of U.S. Patient Access. In this role, Mr. Grausso will lead the Company’s efforts to improve patients’ access to TYMLOS and any other pharmaceutical products that the Company may commercialize in the United States in the future. Danielle Holtschlag, the Company’s Vice President, Head of Sales, will continue to lead the Company’s sales efforts.

Neutral

Radius Health, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 08:40 AM

2021-11-11 13:30:00

Radius Health, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 08:40 AM. Venue: New York, New York, United States.

Neutral

Radius Health, Inc. to Report Q3, 2021 Results on Nov 08, 2021

2021-10-20 19:00:00

Radius Health, Inc. announced that they will report Q3, 2021 results on Nov 08, 2021

Neutral

Radius Health, Inc., Q3 2021 Earnings Call, Nov 08, 2021

2021-10-20 19:00:00

Radius Health, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Positive

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

2021-10-20 12:30:00

the Menarini Group and Radius Health, Inc. announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC). There were two primary endpoints: progression-free survival (PFS) in the overall population and PFS in patients with tumors harboring estrogen receptor 1 (ESR1) mutations. EMERALD met both primary endpoints, showing statistically significant PFS in the overall population and ESR1 mutation subgroup. The safety profile of elacestrant exhibited in EMERALD was similar to that of the previous clinical trial. Given these results, Menarini and Radius plan on proceeding with regulatory submissions in both the United States and European Union in 2022. In 2018, elacestrant received fast track designation from the FDA. Elacestrant is a selective estrogen receptor degrader (SERD). It was being investigated in the Phase 3 EMERALD trial as a potential once daily, oral treatment, in patients with ER+/HER2- mBC. Overall, 466 patients were enrolled in the study, including 220 (47%) with tumors harboring an Estrogen Receptor 1 (ESR1) mutation. ESR1 mutations are important drivers for the development of resistance to endocrine therapy in ER+/HER2- mBC patients.

Positive

Radius Announces Positive Phase 3 Topline Results for TYMLOS® (Abaloparatide) Subcutaneous Injection in Males with Osteoporosis

2021-10-18 12:30:00

Radius Health, Inc. announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The ATOM study met its primary endpoint – the percentage change in lumbar spine (LS) bone mineral density (BMD) compared to placebo – demonstrating statistical significance after 12 months (p-value < 0.0001). Study participants receiving abaloparatide-SC experienced an average increase in LS BMD of 8.5% compared to patients receiving the placebo experiencing an average increase of 1.2%. The study also met secondary endpoints, which measured the percentage change compared to placebo for lumbar spine BMD at 6 months, total hip BMD at 12 months, and femoral neck BMD at 12 months. The safety profile of abaloparatide in the ATOM study was consistent with results in previously reported trials. The Company will complete a full evaluation of the ATOM data and work with investigators to present detailed results at a future medical meeting.

Neutral

Radius Health, Inc. Amends Article X of the Amended and Restated Bylaws

2021-09-27 21:01:00

Effective September 22, 2021, the Board of Directors of Radius Health, Inc. amended Article X of the Company’s Amended and Restated Bylaws to change the federal forum selection from the United States District Court for the District of Massachusetts to the federal district courts of the United States of America as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.

Negative

Radius Health, Inc. Announces Executive Changes

2021-08-26 10:24:00

On August 23, 2021, James G. Chopas tendered his resignation as the Principal Financial Officer, Principal Accounting Officer and Treasurer of Radius Health, Inc., effective as of August 26, 2021. On August 24, 2021, the Company’s Board of Directors appointed Steven Helwig to succeed Mr. Chopas as the Company’s interim Principal Financial Officer, interim Principal Accounting Officer and interim Treasurer, such appointment to become effective as of August 26, 2021. Mr. Helwig has been employed with the Company since August 2015. During his tenure, he has held progressively more senior management roles within the Company’s finance team, most recently as the Company’s Executive Director of Finance – Bone Health and Elacestrant, and prior to that as the Company’s Senior Director of Pipeline Finance and its Director of Finance.

Positive

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

2021-07-22 13:00:00

Radius Health, Inc. announced that it has received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (“FDA”) regarding RAD011, a synthetic cannabidiol oral solution. RAD011 is initially to be utilized for the treatment of Prader-Willi Syndrome (“PWS”). RAD011 has previously been granted Orphan Drug and Fast Track Designation by the FDA. Based on the feedback received, Radius plans on initiating a pivotal Phase 2/3 global study for patients with PWS. The main highlights from the FDA meeting minutes are set out below: Design characteristics and endpoints for a single seamless, pivotal Phase 2/3 study for PWS; Results dependent, a single adequate and well-controlled study could serve as the basis for marketing approval; Acceptability of 505(b)(2) regulatory pathway subject to completion and review of PK bridging and dedicated food effect studies; and Acceptability of nonclinical package to support the pivotal Phase 2/3 study. Radius plans to initiate the pivotal Phase 2/3 study, to be branded as “SCOUT” (Synthetic Cannabidiol Oral Solution), by end of this year or early first quarter of 2022. With this current initiation timeline, it is anticipated top line results would be available in the second half of 2024. The proposed study parameters, informed by several global advisory board meetings completed with leading KOLs, PWS advocacy organizations, and feedback from the FDA, are highlighted below: The pivotal Phase 2/3 study (SCOUT-015) will be a double-blind, placebo-controlled, seamless pivotal Phase 2/3 study in individuals with genetically-confirmed PWS, ages 8 to 65; The seamless design will evaluate safety and tolerability across multiple dose groups in the Phase 2 portion, narrow the dose selection for the Phase 3 portion, and anticipated to enable one study to evaluate efficacy, safety and tolerability; A screening and placebo lead-in period will precede the 26-week maintenance period; Approximately 200 PWS individuals at 30+ global sites are planned for inclusion in SCOUT-015; Primary endpoint: change in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) from baseline; and Eligible individuals have the option to enroll in a long-term extension safety study (SCOUT-016). The Company is working closely with CTI Clinical Trial & Consulting, a world-leading CRO in rare and orphan disease research, to initiate and execute SCOUT-015 and SCOUT-016. Important to the initiation and execution of the SCOUT program, Radius will move forward with RAD011 as not scheduled under the Controlled Substance Act (“CSA”) based on guidance from the Drug Enforcement Administration (“DEA”). The guidance states if a product does not contain any quantity of synthetic THC (or any other controlled substance), it is not controlled under the CSA. RAD011 is not scheduled as it does have traceable amounts of THC.

Neutral

Radius Health, Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-20 21:10:00

Radius Health, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Radius Health, Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-20 21:10:00

Radius Health, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Fundamental Summary

Looking at Radius Health's financials of Q1 reflected unimpressive, mediocre results. This typically translates into the stock performing on par with market performance for the upcoming quarter. As such, Radius Health received an overall score of 61 and a HOLD recommendation.

Radius Health reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 43.16 million compared to USD 56.26 million a year ago. Net loss was USD 18.28 million compared to USD 15.75 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.34 a year ago.

Business Description

Radius Health, a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health was founded in 2003 and is headquartered in Boston, Massachusetts.

Sector Overview

Radius Health is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Radius Health's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 154.1 -15.1% 64
Liabilities 420.1 -3.2% 50
Price to Book -1.5 -16.1% 59
Cash & Equivalents 71.6 -35.8% 44
Equity -265.9 -5.4% 50
EBITDA -47.1 0.1% 71
Total Revenues 216.9 -5.7% 94
Parameter Value Change Score
Return on Equity 30.2 -19.2% 68
Net Cashflow -42.5 -311.5% 64
Capital Expenditure -0.2 -560.7% 37
Asset Turnover 1.2 -2.1% 56
Free Cashflow -0.9 -94.3% 40

* All values are TTM

The below chart reflects Radius Health's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Radius Health's peer average final assessment score stands on 64.0, Radius Health's score is 61.

  •  RDUS
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 14 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Radius Health's stock is now priced above its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the near, medium, and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Radius Health's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 78.

Bullish 78
Close Price 10.5
52W Low 5.53
52W High 22.31
5D MA 10.11
50D MA 7.06
200D MA 10.13
MACD 0.97
RSI 9.15
STOCH 91.48

Balance Sheet Analysis

A few key balance sheet metrics in this report were discouraging. Radius Health did a poor job related to managing cash and cash equivalents this period, which stood at 71.6, representing a -35.8% change from the previous filing. This performance is significantly less impressive than its peers and competitors. Its cash and cash equivalents movement, therefore, received a grade of 44. Also, At filing, Radius Health's liabilities were 420.1, representing a -3.2% change from the previous period. These liabilities metrics show that management has been unsuccessful in encouraging healthy growth while managing liabilities. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 50. However, one encouraging metric, Assets, stood out. Radius Health's management was effective in managing the value of the assets on their balance sheet, which now sits at 154.1 and represents a -15.1% change from the previous report. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its asset component earned a score of 64. Consequently, their balance sheet earned a rank of 54.

Parameter Value Change Score
Assets 154.1 -15.1% 64
Liabilities 420.1 -3.2% 50
Price to Book -1.5 -16.1% 59
Cash & Equivalents 71.6 -35.8% 44
Equity -265.9 -5.4% 50
* All values are TTM

The below chart describes Radius Health's performance as reflected on its balance sheet with respect to its peers. While Radius Health received a balance sheet score of 54, the average of its peers stands on 61.0.

  •  RDUS
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 15 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Radius Health's income statement showed strong financials, specifically Revenue Efficiency and EBITDA. Radius Health did an excellent job managing its revenue efficiency this past period. Radius Health's revenue efficiency is 216.9 according to the metrics in the current filing, which represents a -5.7% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. The company's revenue efficiency, therefore, received a grade of 94. Also, Radius Health's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -47.1, which represents a 0.1% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Consequently, their EBITDA movement received a grade of 71. However, one discouraging result, Return Factors, stood out. In this filing, Radius Health reported a return on equity (ROE) ratio of 30.2, which represents a growth of -19.2%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Consequently, their return factors received a grade of 68. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 82.

Parameter Value Change Score
EBITDA -47.1 0.1% 71
Total Revenues 216.9 -5.7% 94
Return on Equity 30.2 -19.2% 68
* All values are TTM

The below chart describes Radius Health's performance as reflected on its income statement with respect to its peers. While Radius Health received a income statement score of 82 , the average of its peers stands on 67.0.

  •  RDUS
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Amarin Corporation plc 734.5M 95 44 82 63 14 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Radius Health's most recent cash flow report has several troubling numbers, specifically Capital Expenditure and Free Cash flow. Radius Health's management was ineffective in materially improving CapEx, which now sits at -0.2 and represents a -560.7% change from the previous report. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Consequently, their CapEx movement received a grade of 37. Also, Radius Health did a poor job related to generating and maintaining strong free cash flow this period, which stood at -0.9, representing a -94.3% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Its free cash flow movement, therefore, received a grade of 40. That said, one metric, Net Cash Flow, stood out as strongly positive. Radius Health's strong net cash flow numbers, which were -42.5 in this filing, showed a -311.5% change from the last period. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Hence, its net cash flow earned a score of 64. Consequently, its cash flow earned a rank of 57.

Parameter Value Change Score
Net Cashflow -42.5 -311.5% 64
Capital Expenditure -0.2 -560.7% 37
Asset Turnover 1.2 -2.1% 56
Free Cashflow -0.9 -94.3% 40
* All values are TTM

The below chart describes Radius Health's performance as reflected on its cash flow with respect to its peers. While Radius Health received a cash flow score of 57, the average of its peers stands on 70.0.

  •  RDUS
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Amarin Corporation plc 734.5M 52 40 74 55 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 15 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.